Olmita (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Olmita, is a Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination presented as a fixed-dose oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Olmita as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmita, a combination antihypertensive, is indicated for conditions involving elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - High‑risk hypertension: improves blood pressure control in patients with cardiovascular risk factors. - Adjunctive therapy for resistant hypertension: can be added when monotherapy does not achieve target pressure.

Common side effects are generally mild and related to vasodilation or fluid balance.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and redness of the skin. - Fatigue: feeling unusually tired. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Acute kidney injury: sudden reduction in renal function. - Myocardial infarction: chest pain indicative of heart attack.

Before initiating Olmita, clinicians should assess individual risk factors and monitor patients regularly.

- Blood pressure monitoring: check BP after dose adjustments. - Renal function: evaluate serum creatinine and eGFR periodically. - Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents. - Hepatic impairment: use caution in patients with moderate to severe liver disease. - Pregnancy: avoid use unless clearly needed; safety not established. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Olmita may interact with several medicines that affect blood pressure, renal function, or drug metabolism.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: increased risk of hyperkalemia and renal impairment. - NSAIDs: may blunt antihypertensive effect and worsen renal function. - Potassium‑sparing diuretics: heightened risk of hyperkalemia. - Cyclosporine or tacrolimus: can raise olmesartan plasma concentrations. - High‑dose simvastatin: amlodipine can increase statin levels, raising myopathy risk.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: additive blood‑pressure lowering effect. - Beta‑blockers: may enhance overall antihypertensive response. - Rifampin: may reduce olmesartan exposure. - Digoxin: amlodipine can increase digoxin levels. - Alcohol: may potentiate dizziness and hypotension.